EX-99.1 2 ea029290901ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value REDWOOD CITY, Calif., June 1, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale of the Company, a business combination, merger or other strategic transaction, or an orderly wind-down of operations. In connection with this strategic review, Jasper will continue to evaluate cost-saving measures to preserve cash, and plans to continue to maintain compliance with regulatory and financial repor…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Jasper Therapeutics, Inc.
JSPRNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 1, 2026, Jasper Therapeutics, Inc. issued a press release announcing that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.